

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Fok Manson</u> (Last) (First) (Middle) <u>C/O ATHENEX, INC.</u> <u>1001 MAIN STREET, SUITE 600</u> (Street) <u>BUFFALO NY 14203</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Athenex, Inc. [ATNX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>03/25/2020</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/25/2020		P		50,000	A	\$7.25 ⁽¹⁾	1,969,609	D	
Common Stock								678,880	I ⁽²⁾⁽³⁾	By Avalon Biomedical (Management) Limited ⁽²⁾⁽³⁾
Common Stock								107,181 ⁽⁴⁾	I ⁽²⁾⁽³⁾⁽⁴⁾	By Avalon Polytom (HK) Limited ⁽²⁾⁽³⁾⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Option (Right to Buy)	\$4.55							01/02/2014	01/02/2023	Common Stock	80,000	80,000	D	
Stock Option (Right to Buy)	\$4.55							05/13/2014	05/13/2023	Common Stock	48,000	48,000	D	
Stock Option (Right to Buy)	\$4.55							10/11/2015	10/11/2023	Common Stock	20,000	20,000	D	
Stock Option (Right to Buy)	\$4.55							06/12/2016	06/12/2024	Common Stock	40,000	40,000	D	
Stock Option (Right to Buy)	\$7.5							05/18/2016	05/18/2025	Common Stock	48,000	48,000	D	
Stock Option (Right to Buy)	\$9							10/17/2017	10/17/2025	Common Stock	48,000	48,000	D	
Stock Option (Right to Buy)	\$11							(5)	06/13/2027	Common Stock	27,000	27,000	D	
Stock Option (Right to Buy)	\$9							07/17/2018	07/17/2025	Common Stock	54,904	54,904	I ⁽²⁾⁽³⁾	By Avalon Biomedical (Management) Limited ⁽²⁾⁽³⁾

